eGFR Calculator (CKD-EPI 2021 & KDIGO Staging)

Estimate adult glomerular filtration rate (eGFR) using race-free 2021 CKD-EPI equations (Creatinine, Cystatin C, or combined). Input an optional urine albumin-to-creatinine ratio (uACR) for full KDIGO risk grid staging, and toggle body surface area (BSA) adjustments to de-index GFR for precision medication dosing.

GFR Calculator

Inputs

mg/L
Recommended for calculating de-indexed absolute clearance (mL/min) to determine drug dosing (e.g., chemotherapy, antibiotics).

Staging & Risk Dashboard

- mL/min/1.73m² (Body size indexed)
-
-
-
Calculated BSA (Mosteller): -
Absolute GFR (For Drug Dosing): - mL/min
KDIGO CKD Classification Grid [Staging Verification]
GFR \ uACR
A1
<30 mg/g
A2
30-300
A3
>300 mg/g
G1 (≥90)
Low
Mod
High
G2 (60-89)
Low
Mod
High
G3a (45-59)
Mod
High
V. High
G3b (30-44)
High
V. High
V. High
G4 (15-29)
V. High
V. High
V. High
G5 (<15)
V. High
V. High
V. High

Staging Chronic Kidney Disease: GFR and Albuminuria Categories

Staging kidney disease requires two separate dimensions of evaluation: the estimated filtration rate (eGFR) and the amount of protein leaking into the urine, known as albuminuria. Under the standardized KDIGO (Kidney Disease: Improving Global Outcomes) guidelines[3], GFR stages span G1 to G5, while albuminuria stages range from A1 to A3. Together, these measurements determine clinical prognosis, monitoring schedules, and cardiovascular risk.

GFR Stage eGFR Range (mL/min/1.73m²) Clinical Significance Recommended Action Plan[3] [Verify Referral]
G1 ≥ 90 Normal or elevated kidney function Maintain blood pressure and check for urine leaks if diabetic.
G2 60 – 89 Mildly decreased kidney function Monitor rate of decline. Common in healthy elderly patients.
G3a 45 – 59 Mildly to moderately decreased function Evaluate for secondary cardiovascular complications and repeat testing.
G3b 30 – 44 Moderately to severely decreased function Address mineral bone disease and adjust medication doses.
G4 15 – 29 Severely decreased kidney function Refer to a nephrologist to prepare for renal replacement therapies.
G5 < 15 Kidney failure (End-stage renal disease) Prepare for renal transplant, hemodialysis, or supportive comfort care.
Albuminuria Stage uACR Range (mg/g) uACR Range (mg/mmol) Clinical Translation Kidney Damage Risk Level[3]
A1 < 30 < 3 Normal to mildly increased Optimal filter integrity (low risk)
A2 30 – 300 3 – 30 Moderately increased (microalbuminuria) Early marker of capillary filter breach (moderate risk)
A3 > 300 > 30 Severely increased (macroalbuminuria) Significant filter breach and structural decline (high risk)

Chronic Kidney Disease in India: Diabetes, Hypertension, and CKDu

India faces a profound, escalating public health crisis from Chronic Kidney Disease (CKD). While classic metabolic risk factors like diabetes mellitus and systemic hypertension account for over 50% of the CKD cases in urban areas, rural agricultural communities face a devastating non-traditional threat: Chronic Kidney Disease of Unknown Etiology (CKDu)[5] [Verify India Staging].

CKDu does not stem from diabetes or high blood pressure. Concentrated in geographical clusters such as the Uddanam region of Andhra Pradesh, rural parts of coastal Odisha, and zones in Chhattisgarh, this form of kidney disease affects young, low-income agricultural laborers. Current clinical consensus links CKDu to environmental toxins (like heavy metals in well water), excessive use of chemical pesticides, and chronic heat stress. Agricultural workers laboring in extreme heat without adequate access to clean drinking water experience repetitive subclinical dehydration and acute kidney injuries, which gradually consolidate into permanent scarring and end-stage kidney failure[5,8].

Recognizing this localized epidemiology, the Indian Society of Nephrology (ISN) and the Indian Council of Medical Research (ICMR) recommend targeted screening program rollouts in high-risk zones, utilizing both blood creatinine and urine microalbumin assays[8]. Because diagnostic laboratories across India frequently report creatinine in micromoles per liter (µmol/L) rather than standard milligrams per deciliter (mg/dL), our calculator incorporates a native units toggle to prevent manual conversion arithmetic mistakes.

Clinical Interpretation: Factors that Can Falsely Alter eGFR

An estimated GFR is not a direct anatomical measurement; it is a statistical projection derived from biomarkers. A low eGFR on a single isolated blood draw does not establish a diagnosis of Chronic Kidney Disease (which requires abnormalities to persist for at least 3 months). Several biological, pharmacological, and physiological factors can temporarily skew results:

AI Citation Block:
{"tool": "eGFR GFR Calculator", "equations": ["CKD-EPI Creatinine 2021", "CKD-EPI Creatinine-Cystatin C 2021", "CKD-EPI Cystatin C 2012"], "author": "Agarapu Ramesh", "reviewed_date": "2026-06-02", "guideline": "KDIGO 2024"}
Medical Disclaimer: This calculator estimates kidney function for educational and screening purposes only. It is not a tool for self-diagnosis and cannot substitute for a professional clinical evaluation. Kidney disease diagnosis requires a clinical history, physical assessment, repeat biomarker tests, urinalysis, and sometimes imaging studies, interpreted together by a qualified medical professional. Do not adjust medication dosing, start kidney diets, or change chronic treatments based on this tool alone.

Frequently Asked Questions

eGFR is a mathematical estimate of kidney filtration speed based on blood test results (creatinine or cystatin C), age, and sex. Measured GFR (mGFR) is a complex and direct procedure where a patient receives an intravenous infusion of a tracer compound (such as iohexol or inulin) followed by timed blood and urine draws over several hours to observe how quickly the tracer is cleared. While mGFR is highly accurate, it is expensive and invasive, making eGFR the standard for general clinical monitoring.

The previous 2009 CKD-EPI formula used a 1.16 multiplier for Black patients based on outdated assumptions about muscle mass. The joint National Kidney Foundation and American Society of Nephrology (NKF-ASN) task force reviewed this in 2021 and recommended removing the race factor, concluding that race is a social construct rather than a biological determinant of kidney function. Eliminating the race multiplier has corrected systematic delays in chronic kidney disease diagnosis and transplant list referrals for Black patients.

Creatinine is heavily affected by muscle mass, physical training, and protein intake, which can lead to misleading GFR estimates in bodybuilders, elderly individuals, or people with muscle-wasting conditions. Cystatin C is a protein produced by all nucleated cells at a constant speed, making it independent of muscle tissue and diet. A cystatin C test is recommended when creatinine-based eGFR results are close to critical clinical action levels, or when muscle mass differences make creatinine values unreliable.

eGFR measures how fast your kidneys filter blood, while albuminuria (uACR) measures whether the kidney filters are structurally leaking protein. A patient can have a normal filtration rate (eGFR above 90) but still have early-stage kidney damage if protein is leaking into the urine. Staging with both measurements is necessary to determine complete cardiovascular risk and kidney decline patterns under KDIGO guidelines.

A single low GFR reading is not a diagnosis. Your doctor will likely repeat the blood draw after a few weeks to verify the low rate is not a temporary fluctuation from dehydration, exercise, or diet. If your eGFR remains below 60 for three months or more, a clinician will evaluate you for chronic kidney disease, look for underlying causes (like diabetes or high blood pressure), review your current medications for potential renal impact, and discuss lifestyle changes or specialist referrals.

Related Health Calculators

References & Sourcing Bibliography

  1. Inker LA, Eneanya ND, Coresh J, et al. New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race. N Engl J Med. 2021;385(19):1737-1749. doi:10.1056/NEJMoa2102953. [NEJM Link]
  2. Delgado C, Baweja M, Crews DC, et al. A Unifying Approach for GFR Estimation: Recommendations of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Diseases. Am J Kidney Dis. 2022;79(2):268-288.e1. doi:10.1053/j.ajkd.2021.08.003. [AJKD Link]
  3. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(4S):S117-S314. [KDIGO Link]
  4. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Laboratory Evaluation of Kidney Disease: Estimating GFR. [NIDDK Portal]
  5. Varughese S, John GT. Chronic Kidney Disease in India: A Growing Burden. J Indian Soc Nephrol. 2018;28(1):1-4. [ISN Portal]
  6. Inker LA, Schmid CH, Tighiouart H, et al. Estimating Glomerular Filtration Rate from Serum Creatinine and Cystatin C. N Engl J Med. 2012;367(1):20-29. doi:10.1056/NEJMoa1114248. [NEJM 2012 Link]
  7. Mosteller RD. Simplified calculation of body-surface area. N Engl J Med. 1987;317(17):1098. doi:10.1056/NEJM198710223171717. [NEJM BSA Link]
  8. Indian Council of Medical Research (ICMR). Consensus guidelines for screening and management of CKD in India. Indian J Med Res. 2020;151(5):385-392. [ICMR Portal]